Home Cart Sign in  
Chemical Structure| 19309-14-9 Chemical Structure| 19309-14-9

Structure of (E)-Cardamonin
CAS No.: 19309-14-9

Chemical Structure| 19309-14-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cardamonin can supress numerous signaling pathways including TNF-α, COX-2, Wnt/β-catenin and NF-κB, suppresses melanogenesis by inhibition of Wnt/β-catenin signaling, and possesses anti-inflammatory activity via suppression of NF-kB nuclear translocation and Ik-Ba phosphorylation. It is a natural product isolated and purified from the seeds of Alpinia katsumadai Hayata.

Synonyms: (E)-Cardamomin; (E)-Alpinetin chalcone; Cardamonin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (E)-Cardamonin

CAS No. :19309-14-9
Formula : C16H14O4
M.W : 270.28
SMILES Code : O=C(C1=C(OC)C=C(O)C=C1O)/C=C/C2=CC=CC=C2
Synonyms :
(E)-Cardamomin; (E)-Alpinetin chalcone; Cardamonin
InChI Key :NYSZJNUIVUBQMM-BQYQJAHWSA-N
Pubchem ID :641785

Safety of (E)-Cardamonin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 lung cancer cells 1, 5, 10 μM 16 h Inhibited TGF-β1-induced cell invasion Biomol Ther (Seoul). 2015 Mar;23(2):141-8
A549 lung cancer cells 1, 5, 10 μM 5 h Inhibited TGF-β1-induced cell migration Biomol Ther (Seoul). 2015 Mar;23(2):141-8
mouse cardiomyocytes 10 μM 6 h To evaluate the protective effect of CAR on LPS-induced cardiomyocyte contractile defects and its mechanism through Nrf2 and NF-κB signaling pathways. CAR significantly alleviated LPS-induced cardiomyocyte contractile defects, and this protective effect was nullified by the Nrf2 inhibitor ML-385 or the NF-κB activator prostratin. Acta Pharmacol Sin. 2021 Mar;42(3):404-413
HK-2 cells 100 μM 24 h To validate the protective effects of CAD in TGF-β1-stimulated and hypoxia/reoxygenation (H/R)-exposed HK-2 cells. Results showed that CAD significantly inhibited the expression of fibrosis markers (collagen I, α-SMA, collagen III, and fibronectin) induced by TGF-β1 and improved cell viability after H/R injury. J Agric Food Chem. 2023 Sep 13;71(36):13284-13303
mouse primary chondrocytes 2.5-5 μM 48 h To evaluate the protective effect of CAR on iron overload-induced chondrocyte damage, results showed that CAR could reverse the decrease in cell activity caused by iron overload and promote type II collagen expression while inhibiting MMP3 expression Sci Rep. 2023 Aug 23;13(1):13744
A549 lung cancer cells 1, 5, 10 μM 48 h Inhibited TGF-β1-induced epithelial-mesenchymal transition (EMT), including suppression of N-cadherin expression and restoration of E-cadherin expression Biomol Ther (Seoul). 2015 Mar;23(2):141-8
IL-1β-stimulated human OA chondrocytes 5 or 10 µM 24 h To investigate the effect of (E)-Cardamonin on IL-1β-induced iNOS and COX2 expression. Results showed that (E)-Cardamonin significantly inhibited the expression of iNOS and COX2. Antioxidants (Basel). 2021 May 27;10(6):862
Human OA chondrocytes 1, 5, 10, 20, 40 µM 24 or 48 h To evaluate the effect of (E)-Cardamonin on the viability of human chondrocytes. Results showed that (E)-Cardamonin did not significantly affect cell viability at the tested concentrations. Antioxidants (Basel). 2021 May 27;10(6):862
HL-1 cells 10 µM 1 hour To evaluate the effect of CAR on hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury, CAR significantly restored the cardiomyocyte damage caused by co-treatment of H/R and AGEs J Inflamm Res. 2024 Nov 15;17:8861-8879
CCD-18Co cells 5, 10, 20 µM 24 or 48 h Cell viability greater than 50% Pharm Biol. 2022 Dec;60(1):1011-1021
HCT116 cells 5, 10, 20 µM 24 or 48 h Inhibited cell viability, migration, and invasion, down-regulated ADRB2 expression Pharm Biol. 2022 Dec;60(1):1011-1021
Lewis lung carcinoma cells (LLC) 0.1, 1 and 10 μM 24 h Inhibited the invasion and migration of LLC cells PLoS One. 2015 May 21;10(5):e0127778
Lewis lung carcinoma cells (LLC) 0.1, 1 and 10 μM 48 h Inhibited the proliferation of LLC cells PLoS One. 2015 May 21;10(5):e0127778

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57 mice LPS-induced myocardial contractile dysfunction model Oral 20 mg/kg Single dose, lasting for 6 hours To evaluate the protective effect of CAR on LPS-induced myocardial contractile dysfunction and its mechanism. CAR significantly attenuated LPS-induced myocardial contractile dysfunction, oxidative stress, inflammation, and apoptosis, and these protective effects were associated with the regulation of Nrf2 and NF-κB signaling pathways. Acta Pharmacol Sin. 2021 Mar;42(3):404-413
C57BL/6 mice Renal ischemia/reperfusion (I/R) injury and unilateral ureteral obstruction (UUO) model Oral gavage 100 mg/kg I/R model: daily administration for 3 days before I/R; UUO model: daily administration for 7 consecutive days after surgery To evaluate the protective effects of CAD on renal I/R injury and UUO-induced renal fibrosis. Results showed that CAD significantly improved renal function and tissue damage, reduced the expression of inflammatory markers (TNF-α, IL-6, and IL-1β), and inhibited oxidative stress and apoptosis. J Agric Food Chem. 2023 Sep 13;71(36):13284-13303
C57BL/6J mice Iron overload-induced knee osteoarthritis model Gavage 3 mg/kg and 5 mg/kg Once a week for 8 weeks To evaluate the protective effect of CAR on iron overload-induced knee osteoarthritis, results showed that CAR could alleviate articular cartilage destruction and subchondral bone loss Sci Rep. 2023 Aug 23;13(1):13744
C57BL/6 mice Myocardial ischemia/reperfusion injury (MIRI) model Oral 20 mg/kg Single dose 1 hour before reperfusion To evaluate the protective effect of CAR on myocardial ischemia/reperfusion injury (MIRI), CAR significantly reduced myocardial tissue damage and ferroptosis J Inflamm Res. 2024 Nov 15;17:8861-8879
BALB/c nude mice CRC metastasis model Intraperitoneal injection 25 mg/kg Twice a week for 28 days Inhibited metastatic lung nodules Pharm Biol. 2022 Dec;60(1):1011-1021
C57BL/6 mice LLC cell transplantation model Intraperitoneal injection 3.5, 7 and 10.5 mg/kg Once daily for 20 days Inhibited tumor growth and lung metastasis PLoS One. 2015 May 21;10(5):e0127778

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.00mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories